259 related articles for article (PubMed ID: 28549597)
21. Prolactin receptor gene transcriptional control, regulatory modalities relevant to breast cancer resistance and invasiveness.
Kavarthapu R; Dufau ML
Front Endocrinol (Lausanne); 2022; 13():949396. PubMed ID: 36187116
[TBL] [Abstract][Full Text] [Related]
22. Discovery of the improved antagonistic prolactin variants by library screening.
Liu Y; Gong W; Breinholt J; Nørskov-Lauritsen L; Zhang J; Ma Q; Chen J; Panina S; Guo W; Li T; Zhang J; Kong M; Liu Z; Mao J; Christensen L; Hu S; Wang L
Protein Eng Des Sel; 2011 Nov; 24(11):855-60. PubMed ID: 21954059
[TBL] [Abstract][Full Text] [Related]
23. Prolactin- and testosterone-induced carboxypeptidase-D correlates with increased nitrotyrosines and Ki67 in prostate cancer.
Thomas LN; Merrimen J; Bell DG; Rendon R; Too CK
Prostate; 2015 Nov; 75(15):1726-36. PubMed ID: 26202060
[TBL] [Abstract][Full Text] [Related]
24. Targeting Prolactin Receptor (PRLR) Signaling in PRLR-Positive Breast and Prostate Cancer.
O'Sullivan CC; Bates SE
Oncologist; 2016 May; 21(5):523-6. PubMed ID: 27107001
[TBL] [Abstract][Full Text] [Related]
25. Different intracellular signalling pathways triggered by an anti-prolactin receptor (PRLR) antibody: Implication for a signal-specific PRLR agonist.
Kan QE; Su Y; Yang H; Man H
Int J Biol Macromol; 2016 Jan; 82():892-7. PubMed ID: 26526176
[TBL] [Abstract][Full Text] [Related]
26. STAT5a/b Deficiency Delays, but does not Prevent, Prolactin-Driven Prostate Tumorigenesis in Mice.
Boutillon F; Pigat N; Sala LS; Reyes-Gomez E; Moriggl R; Guidotti JE; Goffin V
Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31269779
[TBL] [Abstract][Full Text] [Related]
27. Unexploited therapies in breast and prostate cancer: blockade of the prolactin receptor.
Jacobson EM; Hugo ER; Tuttle TR; Papoian R; Ben-Jonathan N
Trends Endocrinol Metab; 2010 Nov; 21(11):691-8. PubMed ID: 20846877
[TBL] [Abstract][Full Text] [Related]
28. The prolactin receptor mediates HOXA1-stimulated oncogenicity in mammary carcinoma cells.
Hou L; Xu B; Mohankumar KM; Goffin V; Perry JK; Lobie PE; Liu DX
Int J Oncol; 2012 Dec; 41(6):2285-95. PubMed ID: 23064471
[TBL] [Abstract][Full Text] [Related]
29. Elevated collagen-I augments tumor progressive signals, intravasation and metastasis of prolactin-induced estrogen receptor alpha positive mammary tumor cells.
Barcus CE; O'Leary KA; Brockman JL; Rugowski DE; Liu Y; Garcia N; Yu M; Keely PJ; Eliceiri KW; Schuler LA
Breast Cancer Res; 2017 Jan; 19(1):9. PubMed ID: 28103936
[TBL] [Abstract][Full Text] [Related]
30. The Role of Prolactin in Bone Metastasis and Breast Cancer Cell-Mediated Osteoclast Differentiation.
Sutherland A; Forsyth A; Cong Y; Grant L; Juan TH; Lee JK; Klimowicz A; Petrillo SK; Hu J; Chan A; Boutillon F; Goffin V; Egan C; Tang PA; Cai L; Morris D; Magliocco A; Shemanko CS
J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26586670
[TBL] [Abstract][Full Text] [Related]
31. Prolactin-induced prostate tumorigenesis.
Sackmann-Sala L; Goffin V
Adv Exp Med Biol; 2015; 846():221-42. PubMed ID: 25472541
[TBL] [Abstract][Full Text] [Related]
32. Expression of a constitutively active prolactin receptor causes histone trimethylation of the p53 gene in breast cancer.
Tan D; Tang P; Huang J; Zhang J; Zhou W; Walker AM
Chin Med J (Engl); 2014; 127(6):1077-83. PubMed ID: 24622438
[TBL] [Abstract][Full Text] [Related]
33. Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors.
Bogorad RL; Courtillot C; Mestayer C; Bernichtein S; Harutyunyan L; Jomain JB; Bachelot A; Kuttenn F; Kelly PA; Goffin V; Touraine P;
Proc Natl Acad Sci U S A; 2008 Sep; 105(38):14533-8. PubMed ID: 18779591
[TBL] [Abstract][Full Text] [Related]
34. Expression of prolactin and its receptor in human breast carcinoma.
Reynolds C; Montone KT; Powell CM; Tomaszewski JE; Clevenger CV
Endocrinology; 1997 Dec; 138(12):5555-60. PubMed ID: 9389544
[TBL] [Abstract][Full Text] [Related]
35. Prolactin Receptor Expression is an Independent Favorable Prognostic Marker in Human Breast Cancer.
Hachim IY; Hachim MY; Lopez VM; Lebrun JJ; Ali S
Appl Immunohistochem Mol Morphol; 2016 Apr; 24(4):238-45. PubMed ID: 26317306
[TBL] [Abstract][Full Text] [Related]
36. Prolactin in breast and prostate cancer: molecular and genetic perspectives.
Jacobson EM; Hugo ER; Borcherding DC; Ben-Jonathan N
Discov Med; 2011 Apr; 11(59):315-24. PubMed ID: 21524385
[TBL] [Abstract][Full Text] [Related]
37. Stabilization of prolactin receptor in breast cancer cells.
Li Y; Clevenger CV; Minkovsky N; Kumar KG; Raghunath PN; Tomaszewski JE; Spiegelman VS; Fuchs SY
Oncogene; 2006 Mar; 25(13):1896-902. PubMed ID: 16278670
[TBL] [Abstract][Full Text] [Related]
38. Prolactin/androgen-inducible carboxypeptidase-D increases with nitrotyrosine and Ki67 for breast cancer progression in vivo, and upregulates progression markers VEGF-C and Runx2 in vitro.
Thomas LN; Chedrawe ER; Barnes PJ; Too CKL
Breast Cancer Res Treat; 2017 Jul; 164(1):27-40. PubMed ID: 28364216
[TBL] [Abstract][Full Text] [Related]
39. Re-evaluation of the prolactin receptor expression in human breast cancer.
Galsgaard ED; Rasmussen BB; Folkesson CG; Rasmussen LM; Berchtold MW; Christensen L; Panina S
J Endocrinol; 2009 Apr; 201(1):115-28. PubMed ID: 19153125
[TBL] [Abstract][Full Text] [Related]
40. Prolactin Signaling Stimulates Invasion via Na(+)/H(+) Exchanger NHE1 in T47D Human Breast Cancer Cells.
Pedraz-Cuesta E; Fredsted J; Jensen HH; Bornebusch A; Nejsum LN; Kragelund BB; Pedersen SF
Mol Endocrinol; 2016 Jul; 30(7):693-708. PubMed ID: 27176613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
